AbCellera

AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases.[1] The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office.[2] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days."[3] Its platform for single-cell screening was initially developed at the University of British Columbia.[4]

AbCellera
Private
IndustryBiotechnology
HeadquartersVancouver, British Columbia
Websitewww.abcellera.com/ 

History

AbCellera was founded in 2012 by biomedical researchers Carl Hansen and Véronique Lecault. In November 2016, the company received a US$645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis.[5] In September 2018, a $10M series A round of funding was closed.[6] In May 2020, a $105M series B round of funding was closed.[7][8]

In June 2020, the company announced it had begun the world's first study of a potential antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555, in collaboration with Eli Lilly and Company.[9]

Other partnerships include collaborations with GlaxoSmithKline, Novartis, Pfizer, Sanofi and Teva Pharmaceutical Industries.[10]

References
  1. "AbCellera Biologics: Overview". Crunchbase. Retrieved 2020-02-16.
  2. Niiler, Eric (2020-02-14). "Darpa Cranks Up Antibody Research to Stall Coronavirus". Wired. Condé Nast. Retrieved 2020-02-16.
  3. Cumbers, John (2020-02-05). "The Synthetic Biology Companies Racing To Fight Coronavirus". Forbes. Retrieved 2020-02-16.
  4. Shore, Randy (2017-03-03). "B.C.'s biotech leaders are growing up and going global". Vancouver Sun. Postmedia Network. Retrieved 2020-02-16.
  5. "Grant: AbCellera Biologics Inc". Bill & Melinda Gates Foundation. November 2016. Retrieved 2020-02-16.
  6. McGrane, Clare (2018-09-27). "AbCellera raises $10M for machine-learning fueled antibody discovery platform". GeekWire. Retrieved 2020-02-16.
  7. Gormley, Brian (2020-05-27). "AbCellera Banks $105 Million for Antibodies, Including for Covid-19". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-07-21.
  8. Knapp, Alex. "AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases". Forbes. Retrieved 2020-07-21.
  9. "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
  10. "AbCellera collaborates with Novartis for antibody discovery". PharmaTimes. 2019-02-14. Retrieved 2020-02-16.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.